Suppr超能文献

羧基麦芽糖铁脱敏和激发试验的经验

The experiences of ferric carboxymaltose desensitization and provocation.

作者信息

Dindar Çelik Fatma, Aksu Kurtuluş, Akkale Özgür, Çelik Tuğlu Hatice, Yağdıran Melis, Telli Onur, Vural Solak Gürgün Tuğçe, Çelik Enes

机构信息

University of Health Sciences, Ankara Ataturk Sanatorium Training and Research Hospital, Department of Immunology and Allergy, Ankara, Türkiye.

University of Health Sciences, Ankara Ataturk Sanatorium Training and Research Hospital, Department of Pediatric Allergy and Immunology, Ankara, Türkiye.

出版信息

World Allergy Organ J. 2025 Jan 17;18(2):101025. doi: 10.1016/j.waojou.2024.101025. eCollection 2025 Feb.

Abstract

BACKGROUND

To present the characteristics of drug hypersensitivity reactions (DHR) among iron preparations and to describe the outcomes of rapid drug desensitization (RDD) and drug provocation tests (DPT) of ferric carboxymaltose (FCM).

METHODS

The retrospective descriptive study comprised patients with hypersensitivy to iron supplements. Low-risk according to the index reaction with iron, 10 patients underwent a 4-step DPT with FCM; an 11-step RDD protocol was administered to 21 patients not classified as low-risk. RDD success was evaluated for each cycle separately, defining successful completion as the implementation of all steps in both RDD and DPT protocols without subsequent early and/or late reactions.

RESULTS

Among the 21 patients (mean age: 41.73 ± 10.98 years, all female) hypersensitive to iron underwent FCM RDD, 20 patients (95.2%) successfully completed FCM treatment with RDD. RDD failed in only 1 patient (4.8%). The total number of desensitization cycles was 29, of which 28 (96.5%) were successful. Urticaria was the most common breakthrough hypersensitivity reaction and observed in 7 (33.3%) patients. Ten patients received FCM with DPT. The iron replacement therapy for these 10 patients was successfully completed. Urticaria developed in 2 patients after the completion of DPT.

CONCLUSIONS

RDD is a dependable procedure facilitating the efficient delivery and completion of FCM treatments in patients with iron hypersensitivity. Additionally, FCM can be applied with DPT in low-risk patients.

摘要

背景

介绍铁剂药物过敏反应(DHR)的特征,并描述羧基麦芽糖铁(FCM)快速药物脱敏(RDD)和药物激发试验(DPT)的结果。

方法

这项回顾性描述性研究纳入了对铁补充剂过敏的患者。根据铁剂引发的反应风险较低,10例患者接受了FCM的4步DPT;21例未被归类为低风险的患者接受了11步RDD方案。分别评估每个周期的RDD成功率,将成功完成定义为在RDD和DPT方案中实施所有步骤,且无随后的早期和/或晚期反应。

结果

在21例对铁过敏的患者(平均年龄:41.73±10.98岁,均为女性)中接受了FCM RDD,20例患者(95.2%)通过RDD成功完成了FCM治疗。仅1例患者(4.8%)RDD失败。脱敏周期总数为29个,其中28个(96.5%)成功。荨麻疹是最常见的突破性过敏反应,7例(33.3%)患者出现该反应。10例患者接受了FCM的DPT。这10例患者的铁替代治疗成功完成。DPT完成后,2例患者出现荨麻疹。

结论

RDD是一种可靠的方法,有助于铁过敏患者高效地接受和完成FCM治疗。此外,FCM可用于低风险患者的DPT。

相似文献

1
The experiences of ferric carboxymaltose desensitization and provocation.羧基麦芽糖铁脱敏和激发试验的经验
World Allergy Organ J. 2025 Jan 17;18(2):101025. doi: 10.1016/j.waojou.2024.101025. eCollection 2025 Feb.
3
Rapid drug desensitization to taxanes: a descriptive study from Turkey.紫杉醇快速脱敏:来自土耳其的描述性研究。
J Oncol Pharm Pract. 2024 Dec;30(8):1358-1363. doi: 10.1177/10781552231213318. Epub 2023 Nov 7.

本文引用的文献

1
Classics in Chemical Neuroscience: Deliriant Antihistaminic Drugs.经典化学神经科学:致幻性抗组胺药物。
ACS Chem Neurosci. 2024 Nov 6;15(21):3848-3862. doi: 10.1021/acschemneuro.4c00505. Epub 2024 Oct 15.
3
EAACI/ENDA position paper on drug provocation testing.EAACI/ENDA 药物激发试验立场文件。
Allergy. 2024 Mar;79(3):565-579. doi: 10.1111/all.15996. Epub 2023 Dec 28.
4
IV iron formulations and use in adults.静脉铁剂制剂及在成人中的应用。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):622-629. doi: 10.1182/hematology.2023000495.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验